Thomas Hope

MD

Radiologist
Radiologic therapy researcher and avid hiker

Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI – to stage cancer in patients.

Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

  • Education

    Stanford University School of Medicine, 2007

  • Residencies

    UCSF Medical Center, Diagnostic Radiology, 2012

  • Fellowships

    Stanford Hospital and Clinics, Nuclear Medicine and Body MRI , 2013

  • Board Certifications

    Nuclear Medicine, American Board of Nuclear Medicine

    Diagnostic Radiology, American Board of Radiology

  • Academic Title

    Associate Professor

Conditions I specialize in

Where I see patients (4)

    Selected research

    Decorative Caduceus

    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

    The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...

    Recruiting

    Decorative Caduceus

    Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastat...

    PSA progression is defined as a rise in PSA at > 12 weeks by more than 25% and more than 2ng/mL above the nadir (lowest PSA point).

    Recruiting

    Decorative Caduceus

    18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

    Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...

    Recruiting

    Decorative Caduceus

    Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

    Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.

    Recruiting

    Decorative Caduceus

    Mechanisms of Resistance to PSMA Radioligand Therapy

    The unit density sphere model will be implemented using OLINDA, a second-generation personal computer software for internal dose assessment in nuclear medicine to measure mean dose across all metastatic lesions. This approach uses...

    Recruiting

    Decorative Caduceus

    Imaging of Solid Tumors Using FAP-2286

    The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI ...

    Recruiting

    Contact me

    Share